Search Results - "Gilbride, Jennifer"

Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus by Ginzler, Ellen, Guedes Barbosa, Luiz Sergio, D'Cruz, David, Furie, Richard, Maksimowicz‐McKinnon, Kathleen, Oates, James, Santiago, Mittermayer Barreto, Saxena, Amit, Sheikh, Saira, Bass, Damon L., Burriss, Susan W., Gilbride, Jennifer A., Groark, James G., Miller, Michelle, Pierce, Amy, Roth, David A., Ji, Beulah

“…Objective Enrollment of patients of Black African ancestry with systemic lupus erythematosus (SLE) in phase II and phase III of the belimumab trials was not…”
Get full text

Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population by Yu, Xueqing, Chen, Nan, Xue, Jun, Mok, Chi Chiu, Bae, Sang-Cheol, Peng, Xiaomei, Chen, Wei, Ren, Hong, Li, Xiao, Noppakun, Kajohnsak, Gilbride, Jennifer A., Green, Yulia, Ji, Beulah, Liu, Chang, Madan, Anuradha, Okily, Mohamed, Tang, Chun-Hang, Roth, David A.

“…Belimumab improved kidney outcomes in patients with active lupus nephritis (LN) in BLISS-LN, leading to its approval in the United States and the European…”
Get full text

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus by Urowitz, Murray B., Aranow, Cynthia, Asukai, Yumi, Bass, Damon L., Bruce, Ian N., Chauhan, Deven, Dall'Era, Maria, Furie, Richard, Fox, Norma Lynn, Gilbride, Jennifer A., Hammer, Anne, Ginzler, Ellen M., Gonzalez‐Rivera, Tania, Levy, Roger A., Merrill, Joan T., Quasny, Holly, Roth, David A., Stohl, William, Vollenhoven, Ronald, Wallace, Daniel J., Petri, Michelle

“…Organ damage is a key determinant of poor long‐term prognosis and early death in patients with systemic lupus erythematosus (SLE). Prevention of damage is a…”
Get full text

Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis by Chesnut, Charles H, Skag, Arne, Christiansen, Claus, Recker, Robert, Stakkestad, Jacob A, Hoiseth, Arne, Felsenberg, Dieter, Huss, Hermann, Gilbride, Jennifer, Schimmer, Ralph C, Delmas, Pierre D

“…Oral daily (2.5 mg) and intermittent ibandronate (between‐dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946…”
Get full text

1104 Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) With Relapsed and Newly Diagnosed Active Lupus Nephritis (LN) by Anders, Hans-Joachim, Rovin, Brad H, Zhao, Ming-Hui, Malvar, Ana, Hiromura, Keiju, Leone, Angela Jones, Gonzalez-Rivera, Tania, Gilbride, Jennifer, Madan, Anuradha, Green, Yulia, Roth, David A

“…BackgroundDespite standard therapy (ST) for LN, only 20–40% of pts achieve Complete Renal Response (CRR) at 0.5–1 year and 20–25% relapse in 3–5 years…”
Get full text

A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis by Rovin, Brad H, Furie, Richard, Teng, Y K Onno, Contreras, Gabriel, Malvar, Ana, Yu, Xueqing, Ji, Beulah, Green, Yulia, Gonzalez-Rivera, Tania, Bass, Damon, Gilbride, Jennifer, Tang, Chun-Hang, Roth, David A

“…We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN), a Phase 3, multinational, double-blind, 104-week trial, in…”
Get more information

Post Hoc Analyses of Biomarkers Predictive of a Renal Response to Intravenous (IV) Belimumab (BEL) Plus Standard Therapy (ST) in Patients with Lupus Nephritis (LN): SA-PO881 by Rovin, Brad H., Furie, Richard, Malvar, Ana, Aranow, Cynthia, Pego-Reigosa, José M., Zakharova, Elena, Schwarting, Andreas, Jones-Leone, Angela R., Gilbride, Jennifer A., Ji, Beulah, Roth, David A., Curtis, Paula S., Maurik, André van

Get full text

Effects of Belimumab (BEL) on Renal Outcomes in Patients (pts) with Relapsed and Newly Diagnosed Active Lupus Nephritis (LN): SA-OR32 by Anders, Hans J., Rovin, Brad H., Zhao, Ming Hui, Malvar, Ana, Hiromura, Keiju, Jones-Leone, Angela R., González-Rivera, Tania, Gilbride, Jennifer A., Madan, Anuradha, Green, Yulia, Roth, David A.

Get full text

Belimumab (BEL) Improves Renal Outcomes in Active Lupus Nephritis (LN): A Phase 3 Randomized, Placebo (PBO)-Controlled Trial: SU-OR34 by Rovin, Brad H., Houssiau, Frederic, Furie, Richard, Malvar, Ana, Teng, Yoe Kie Onno, Mok, Chi chiu, Contreras, Gabriel, Yu, Xueqing, Dolff, Sebastian, Ji, Beulah, Roth, David A., Kleoudis, Christi, Makowiak, Susan, Madan, Anuradha, Gilbride, Jennifer, Green, Yulia

Get full text

Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry by Juliao, Patricia, Wurst, Keele, Pimenta, Jeanne M., Gemzoe, Kim, Landy, Helain, Moody, M. Anthony, Tilson, Hugh, Covington, Deborah, Moore, Tammy, Marino, Rebecca, Gilbride, Jennifer, Liu, Andrew, Meizlik, Paige, Petri, Michelle

“…Background Belimumab is approved for active, autoantibody‐positive systemic lupus erythematosus (SLE) and lupus nephritis, but limited data exist regarding its…”
Get full text

Early administration of oral oseltamivir increases the benefits of influenza treatment by Aoki, F. Y., Macleod, M. D., Paggiaro, P., Carewicz, O., El Sawy, A., Wat, C., Griffiths, M., Waalberg, E., Ward, P.

“…Our objective was to evaluate the benefit of early treatment of influenza illness using oral oseltamivir. This open-label, multicentre international study…”
Get full text